[1] |
LONDON M, GALLO E. Epidermal growth factor receptor(EGFR)involvement in epithelial-derived cancers and its current antibody-based immunotherapies[J]. Cell Biol Int, 2020, 44(6):1267-1282. DOI: 10.1002/cbin.11340.
|
[2] |
YU J F, FANG T, YUN C Y,et al. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers[J]. Front Mol Biosci, 2022, 9:847835. DOI: 10.3389/fmolb.2022.847835.
|
[3] |
GRAVALOS C, JIMENO A. HER2 in gastric cancer:a new prognostic factor and a novel therapeutic target[J]. Ann Oncol, 2008, 19(9):1523-1529. DOI: 10.1093/annonc/mdn169.
|
[4] |
ZHOU L, XU H Y, Li S M,et al. Study RC48-C014:Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma[J]. Journal of Clinical Oncology, 2022, 40(6_suppl):515. DOI: 10.1200/jco.2022.40.6_suppl.515.
|
[5] |
ZHANG L L, HAMDANI O, GJOERUP O,et al. ERBB2 copy number as a quantitative biomarker for real-world outcomes to anti-human epidermal growth factor receptor 2 therapy in advanced gastroesophageal adenocarcinoma[J]. JCO Precis Oncol, 2022, 6:e2100330. DOI: 10.1200/PO.21.00330.
|
[6] |
AJANI J A, D'AMICO T A, BENTREM D J,et al. Gastric cancer,version 2.2022,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2):167-192. DOI: 10.6004/jnccn.2022.0008.
|
[7] |
YUN T, WANG S N, JIANG B,et al. Significance of detection of the HER2 gene and PD-1/PD-L1 in gastric cancer[J]. J Oncol, 2020, 2020:8678945. DOI: 10.1155/2020/8678945.
|
[8] |
YANG T, XU R, YOU J H,et al. Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer[J]. BMC Cancer, 2022, 22(1):1168. DOI: 10.1186/s12885-022-10262-7.
|
[9] |
KIM C, LEE C K, CHON H J,et al. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer[J]. Oncotarget, 2017, 8(69):113494-113501. DOI: 10.18632/oncotarget.23054.
|
[10] |
ABDOLLAHPOUR-ALITAPPEH M, LOTFINIA M, GHARIBI T,et al. Antibody-drug conjugates(ADCs)for cancer therapy:strategies,challenges,and successes[J]. J Cell Physiol, 2019, 234(5):5628-5642. DOI: 10.1002/jcp.27419.
|
[11] |
JIN Y M, EDALATIAN ZAKERI S, BAHAL R,et al. New technologies bloom together for bettering cancer drug conjugates[J]. Pharmacol Rev, 2022, 74(3):680-711. DOI: 10.1124/pharmrev.121.000499.
|
[12] |
YAGHOUBI S, KARIMI M H, LOTFINIA M,et al. Potential drugs used in the antibody-drug conjugate(ADC)architecture for cancer therapy[J]. J Cell Physiol, 2020, 235(1):31-64. DOI: 10.1002/jcp.28967.
|
[13] |
中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)胃癌诊疗指南-2022[M]. 北京:人民卫生出版社,2022.
|
[14] |
INDINI A, RIJAVEC E, GROSSI F. Trastuzumab deruxtecan:changing the destiny of HER2 expressing solid tumors[J]. Int J Mol Sci, 2021, 22(9):4774. DOI: 10.3390/ijms22094774.
|
[15] |
OGITANI Y, AIDA T, HAGIHARA K,et al. DS-8201a,a novel HER2-targeting ADC with a novel DNA topoisomerase Ⅰ inhibitor,demonstrates a promising antitumor efficacy with differentiation from T-DM1[J]. Clin Cancer Res, 2016, 22(20):5097-5108. DOI: 10.1158/1078-0432.CCR-15-2822.
|
[16] |
OGITANI Y, HAGIHARA K, OITATE M,et al. Bystander killing effect of DS-8201a,a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate,in tumors with human epidermal growth factor receptor 2 heterogeneity[J]. Cancer Sci, 2016, 107(7):1039-1046. DOI: 10.1111/cas.12966.
|
[17] |
ClinicalTrials.gov. DS-8201a in human epidermal growth factor receptor 2(HER2)-expressing gastric cancer [DESTINY-Gastric01][EB/OL]. (2020-11-27)[2023-04-15].
|
[18] |
YAMAGUCHI K, BANG Y J, IWASA S,et al. 1422MO Trastuzumab deruxtecan(T-DXd;DS-8201)in patients with HER2-low,advanced gastric or gastroesophageal junction(GEJ)adenocarcinoma:results of the exploratory cohorts in the phase Ⅱ,multicenter,open-label DESTINY-Gastric01 study[J]. Ann Oncol, 2020, 31:S899-900. DOI: 10.1016/j.annonc.2020.08.1928.
|
[19] |
YAMAGUCHI K, BANG Y J, IWASA S,et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma:exploratory cohort results in a phaseⅡ trial[J]. J Clin Oncol, 2023, 41(4):816-825. DOI: 10.1200/JCO.22.00575.
|
[20] |
Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma(EPOC2003)[C]. 2022 ASCO,Abstract TPS4161.
|
[21] |
PENG Z, LIU T S, WEI J,et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phaseⅡ study[J]. Cancer Commun, 2021, 41(11):1173-1182. DOI: 10.1002/cac2.12214.
|
[22] |
CHEN Z H, YUAN J J, XU Y Y,et al. From AVATAR mice to patients:RC48-ADC exerted promising efficacy in advanced gastric cancer with HER2 expression[J]. Front Pharmacol, 2021, 12:757994. DOI: 10.3389/fphar.2021.757994.
|
[23] |
LI H W, YU C, JIANG J,et al. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer[J]. Cancer Biol Ther, 2016, 17(4):346-354. DOI: 10.1080/15384047.2016.1139248.
|
[24] |
|
[25] |
ClinicalTrials.gov. Study of RC48-ADC Administered Intravenously to Subjects with HER2-Positive in Advanced Malignant Solid Tumors[EB/OL]. (2020-11-27)[2023-04-15].
|
[26] |
XU Y Y, WANG Y K, GONG J F,et al. PhaseⅠ study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors[J]. Gastric Cancer, 2021, 24(4):913-925. DOI: 10.1007/s10120-021-01168-7.
|
[27] |
国家药品监督管理局. 国家药监局附条件批准注射用维迪西妥单抗上市[EB/OL]. (2021-06-09)[2023-04-15].
|
[28] |
ClinicalTrials.gov. Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients with HER2 Positive Gastric and GEJ Adenocarcinoma[EB/OL]. (2020-11-27)[2023-04-15].
|
[29] |
ClinicalTrials.gov. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects with the Overexpression of HER2[EB/OL]. (2022-01-13)[2023-04-15].
|
[30] |
ClinicalTrials.gov. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS)in Advanced Gastric Cancer(RCTS)[EB/OL]. (2022-10-19)[2023-04-15].
|
[31] |
BAROK M, JONCOUR V L, MARTINS A,et al. ARX788,a novel anti-HER2 antibody-drug conjugate,shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer[J]. Cancer Lett, 2020, 473:156-163. DOI: 10.1016/j.canlet.2019.12.037.
|
[32] |
SKIDMORE L, SAKAMURI S, KNUDSEN N A,et al. ARX788,a site-specific anti-HER2 antibody-drug conjugate,demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers[J]. Mol Cancer Ther, 2020, 19(9):1833-1843. DOI: 10.1158/1535-7163.MCT-19-1004.
|
[33] |
BAROK M, JONCOUR V L, MARTINS A,et al. ARX788,a novel anti-HER2 antibody-drug conjugate,shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer[J]. Cancer Lett, 2020, 473:156-163. DOI: 10.1016/j.canlet.2019.12.037.
|
[34] |
ZHANG Y, QIU M Z, WANG J F,et al. Phase 1 multicenter,dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma[J]. Cell Rep Med, 2022, 3(11):100814. DOI: 10.1016/j.xcrm.2022.100814.
|
[35] |
Clinicaltrials. searchlistdetail. ARX788在HER2阳性晚期胃癌和胃食管连接部腺癌患者中的有效性及安全性研究[EB/OL]. (2021-07-12)[2023-04-15].
|
[36] |
EDUPUGANTI V V S R, TYNDALL J D A T D A, GAMBLE A B. Self-immolative linkers in prodrugs and antibody drug conjugates in cancer treatment[J]. Recent Pat Anticancer Drug Discov, 2021, 16(4):479-497. DOI: 10.2174/1574892816666210509001139.
|
[37] |
SHIN S H, PARK Y H, PARK S S,et al. An elaborate new linker system significantly enhances the efficacy of an HER2-antibody-drug conjugate against refractory HER2-positive cancers[J]. Adv Sci, 2021, 8(23):e2102414. DOI: 10.1002/advs.202102414.
|
[38] |
ClinicalTrials.gov. Phase 1 Study of FS-1502 in Patients with HER2 Expressed Advanced Solid Tumors and Breast Cancer[EB/OL]. (2022-05-20)[2023-04-15].
|
[39] |
LI H, ZHANG X, XU Z Y,et al. Preclinical evaluation of MRG002,a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors[J]. Antib Ther, 2021, 4(3):175-184. DOI: 10.1093/abt/tbab017.
|
[40] |
YU J F, FANG T, YUN C Y,et al. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers[J]. Front Mol Biosci, 2022, 9:847835. DOI: 10.3389/fmolb.2022.847835.
|
[41] |
ClinicalTrials.gov. A Study of MRG002 in the Treatment of Patients with HER2-positive Advanced Solid Tumors[EB/OL]. (2021-12-03)[2023-04-15].
|
[42] |
ClinicalTrials.gov. A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer[EB/OL]. (2022-02-23)[2023-04-15].
|
[43] |
ClinicalTrials.gov. PF-06804103 Dose Escalation in HER2 Positive and Negative(Negative Only in Part 2)Solid Tumors[EB/OL]. (2022-03-18)[2023-04-15].
|
[44] |
ClinicalTrials.gov. A Dose-escalation,Expansion Study of ARX788,in Advanced Solid Tumors Subjects with HER2 Expression(ACE-Pan Tumor 01)[EB/OL]. (2023-04-10)[2023-04-15].
|
[45] |
ClinicalTrials.gov. A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction(GEJ)Cancer[EB/OL]. (2022-05-06)[2023-04-15].
|
[46] |
ClinicalTrials.gov. A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2[EB/OL]. (2023-03-15)[2023-04-15].
|
[47] |
ClinicalTrials.gov. ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel with Trastuzumab Duocarmazine(SYD985)in Patients with Metastatic Cancer[EB/OL]. (2023-03-24)[2023-04-15].
|
[48] |
MAHALINGAIAH P K, CIURLIONIS R, DURBIN K R,et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates[J]. Pharmacol Ther, 2019, 200:110-125. DOI: 10.1016/j.pharmthera.2019.04.008.
|
[49] |
YU M H, LIANG Y, LI L H,et al. Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer[J]. Transl Oncol, 2023, 29:101624. DOI: 10.1016/j.tranon.2023.101624.
|
[50] |
GARCÍA-ALONSO S, OCAÑA A, PANDIELLA A. Trastuzumab emtansine:mechanisms of action and resistance,clinical progress,and beyond[J]. Trends Cancer, 2020, 6(2):130-146. DOI: 10.1016/j.trecan.2019.12.010.
|
[51] |
DÍAZ-RODRÍGUEZ E, GANDULLO-SÁNCHEZ L, OCAÑA A,et al. Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs[J]. Cancers, 2021, 14(1):154. DOI: 10.3390/cancers14010154.
|
[52] |
BON G, PIZZUTI L, LAQUINTANA V,et al. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade:the SePHER Study[J]. J Exp Clin Cancer Res, 2020, 39(1):279. DOI: 10.1186/s13046-020-01797-3.
|
[53] |
GINZEL J D, ACHARYA C R, LUBKOV V,et al. HER2 isoforms uniquely program intratumor heterogeneity and predetermine breast cancer trajectories during the occult tumorigenic phase[J]. Mol Cancer Res, 2021, 19(10):1699-1711. DOI: 10.1158/1541-7786.MCR-21-0215.
|
[54] |
WANG S, ZHAO Y Z, SONG Y G,et al. ERBB2D16 expression in HER2 positive gastric cancer is associated with resistance to trastuzumab[J]. Front Oncol, 2022, 12:855308. DOI: 10.3389/fonc.2022.855308.
|